1Endocrinology Unit, Department of Clinical Sciences and Community Health, University of Milan, Via Francesco Sforza, 35-20122 Milan, Italy.
2Endocrinology and Metabolic Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Clin Epigenetics. 2018 Feb 6;10:16. doi: 10.1186/s13148-018-0449-4. eCollection 2018.
Pseudohypoparathyroidism type 1B (PHP1B; MIM#603233) is a rare imprinting disorder (ID), associated with the GNAS locus, characterized by parathyroid hormone (PTH) resistance in the absence of other endocrine or physical abnormalities. Sporadic PHP1B cases, with no known underlying primary genetic lesions, could represent true stochastic errors in early embryonic maintenance of methylation. Previous data confirmed the existence of different degrees of methylation defects associated with PHP1B and suggested the presence of mosaicism, a phenomenon already described in the context of other IDs.
With respect to mosaic conditions, the study of multiple tissues is a necessary approach; thus, we investigated somatic cell lines (peripheral blood and buccal epithelium and cells from the urine sediment) descending from different germ layers from 19 PHP patients (11 spor-PHP1B, 4 GNAS mutated PHP1A, and 4 PHP with no GNAS (epi)genetic defects) and 5 healthy controls. We identified 11 patients with epigenetic defects, further subdivided in groups with complete or partial methylation defects. The recurrence of specific patterns of partial methylation defects limited to specific CpGs was confirmed by checking methylation profiles of spor-PHP1B patients diagnosed in our lab ( = 56). Underlying primary genetic defects, such as uniparental disomy or deletion, potentially causative for the detected partial methylation were excluded in all samples.
Our data showed no differences of methylation levels between organs and tissues from the same patient, so we concluded that the epimutation occurred in early post-zygotic phases and that the partial defects were mosaics. The number of patients with no detectable (epi)genetic GNAS defects was too small to exclude epimutations occurring in later post-zygotic phases, affecting only selected tissues different from blood, thus leading to underdiagnosis during routine molecular diagnosis. Finally, we found no correlation between methylation ratios, representing the proportion of epimutated cells, and the clinical presentation, further confirming the hypothesis of a threshold effect of the GNAS loss of imprinting leading to an "all-or-none" phenotype.
假性甲状旁腺功能减退症 1B 型(PHP1B;MIM#603233)是一种罕见的印迹障碍(ID),与 GNAS 基因座相关,其特征是甲状旁腺激素(PTH)抵抗,而没有其他内分泌或身体异常。没有已知潜在原发性遗传病变的散发性 PHP1B 病例可能代表早期胚胎维持甲基化过程中的真正随机错误。先前的数据证实了与 PHP1B 相关的不同程度甲基化缺陷的存在,并表明存在嵌合体现象,这种现象已经在其他 ID 中描述过。
关于嵌合体情况,对多个组织进行研究是必要的方法;因此,我们研究了来自 19 名 PHP 患者(11 名散发性 PHP1B、4 名 GNAS 突变 PHP1A 和 4 名无 GNAS(epi)遗传缺陷的 PHP)和 5 名健康对照的不同胚层衍生的体细胞系(外周血、口腔上皮和尿沉渣细胞)。我们发现 11 名患者存在表观遗传缺陷,进一步分为完全或部分甲基化缺陷组。通过检查我们实验室诊断的散发性 PHP1B 患者的甲基化谱,证实了特定部分甲基化缺陷模式的重现,这些缺陷模式仅限于特定的 CpG。所有样本均排除了潜在的单亲二倍体或缺失等潜在的部分甲基化原因。
我们的数据显示,同一患者的器官和组织之间的甲基化水平没有差异,因此我们得出结论,该表观突变发生在合子后早期阶段,且部分缺陷是嵌合体。没有检测到可检测的(epi)遗传 GNAS 缺陷的患者数量太少,无法排除仅影响与血液不同的选定组织的合子后后期发生的表观突变,从而导致常规分子诊断中的漏诊。最后,我们没有发现甲基化比率(代表受影响的嵌合体细胞的比例)与临床表现之间的相关性,进一步证实了 GNAS 印记丢失导致“全或无”表型的阈值效应假说。